JPS6315957A - Tube for intravenous injection of nitroglycerine - Google Patents
Tube for intravenous injection of nitroglycerineInfo
- Publication number
- JPS6315957A JPS6315957A JP61156219A JP15621986A JPS6315957A JP S6315957 A JPS6315957 A JP S6315957A JP 61156219 A JP61156219 A JP 61156219A JP 15621986 A JP15621986 A JP 15621986A JP S6315957 A JPS6315957 A JP S6315957A
- Authority
- JP
- Japan
- Prior art keywords
- tube
- tng
- intravenous injection
- nitroglycerine
- nitroglycerin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 title claims description 31
- 229960003711 glyceryl trinitrate Drugs 0.000 title claims description 8
- 238000010253 intravenous injection Methods 0.000 title claims description 6
- 239000000006 Nitroglycerin Substances 0.000 claims description 7
- 229920001862 ultra low molecular weight polyethylene Polymers 0.000 claims description 4
- 230000005484 gravity Effects 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 description 6
- 229920000915 polyvinyl chloride Polymers 0.000 description 4
- 239000004800 polyvinyl chloride Substances 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000007654 immersion Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
Abstract
(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
【発明の詳細な説明】
（産業上の利用分野）
本発明は、ニトログリセリンを静脈注入するための医療
用具に使用されるチューブに関する。DETAILED DESCRIPTION OF THE INVENTION Field of the Invention The present invention relates to a tube used in a medical device for intravenously injecting nitroglycerin.
（従来の技術及び問題点）
最近、静注用ニトログリセリン（以下ＴＮＧと称す）の
持接続点滴法、注入法が急性心筋梗塞、冠動脈手術およ
び低血圧麻酔等に使用され注目を浴びている。(Prior Art and Problems) Recently, the continuous drip method and injection method of intravenous nitroglycerin (hereinafter referred to as TNG) have been attracting attention as they are used for acute myocardial infarction, coronary artery surgery, hypotensive anesthesia, etc.
ＴＮＧの投与には、輸液セット、エクステンションチュ
ーブ等の医療用具により実施されている。TNG is administered using medical devices such as infusion sets and extension tubes.
前記医療用具は、通常、ポリ塩化ビニルから形成されて
いる。しかしながら、ポリ塩化ビニル製のチューブでは
、ＴＮＧ投与時において、ＴＮＧのチューブへの吸着量
が多く、正確なＴＮＧの投与ができない欠点があった。The medical device is typically formed from polyvinyl chloride. However, the tube made of polyvinyl chloride has the disadvantage that when administering TNG, a large amount of TNG is adsorbed to the tube, making it impossible to administer TNG accurately.
また、通常ＴＮＧの吸着が少ないと言われている低密度
または、高密度のポリエチレンは、柔軟性がなく、柔軟
性が必要不可欠である前記医療用具には、使用できなか
った。In addition, low-density or high-density polyethylene, which is generally said to have a low adsorption of TNG, has no flexibility and cannot be used in the above-mentioned medical devices where flexibility is essential.
（問題点を解決するための手段）
そこで本発明は、ニトログリセリン静注用チューブとし
て、比％０．８９以下の超低密度ポリエチレンからなる
チューブがＴＮＧの吸着量が少なくかつ適度に柔軟性を
有し、ニトログリセリン静注用チューブとして好適であ
ることを見い出した。(Means for Solving the Problems) Therefore, the present invention provides a tube made of ultra-low density polyethylene with a ratio of 0.89 or less as a tube for intravenous nitroglycerin injection, which has a small adsorption amount of TNG and has appropriate flexibility. It has been found that the tube is suitable for use as a tube for intravenous injection of nitroglycerin.
本発明のニトログリセリン静注用チューブは、輸液セッ
ト、カテーテル、エクステンションチューブ等の医療用
具に使用される。The nitroglycerin intravenous injection tube of the present invention is used for medical devices such as infusion sets, catheters, and extension tubes.
（実施例） 本発明のチューブは次のように製造される。(Example) The tube of the present invention is manufactured as follows.
比重０．８９の超低密度ポリエチレンのベレットを１４
０〜１７０℃で押出成形機によりチューブ状（内径２．
１ ｍｍＸ外径３．３ｍ１ｍ Ｘ長さ２０００ｍｍ）に
成形した。14 pellets of ultra-low density polyethylene with a specific gravity of 0.89
It is molded into a tube shape (inner diameter 2.
1 mm x outer diameter of 3.3 m and 1 m x length of 2000 mm).
該チューブを用いてＴＮＧの吸着試験を次のように行な
った。A TNG adsorption test was conducted using the tube as follows.
ＴＮＧ （日本化薬製）０．１１ｇを、２．０１の水で
溶解し、ＴＮＧ水溶液を調整した。0.11 g of TNG (manufactured by Nippon Kayaku) was dissolved in 2.01 g of water to prepare a TNG aqueous solution.
前記押出成形機により成形したチューブを、０．１ｍｇ
の重量となるように切断し、これを、試験管において、
前記ＴＮＧ水溶液中に、浸漬し室温で４８時間放置した
。0.1 mg of the tube molded by the extrusion molding machine
Cut it to a weight of , and place it in a test tube.
It was immersed in the TNG aqueous solution and left at room temperature for 48 hours.
その後、高速液体クロマトグラフィー（ＨＰＬＣ）によ
り、ＴＮＧ水溶液中のＴＮＧ濃度を測定し、次式により
ＴＮＧの残存率を算出した。Thereafter, the TNG concentration in the TNG aqueous solution was measured by high performance liquid chromatography (HPLC), and the residual rate of TNG was calculated using the following formula.
残存率＝ （Ａ／Ｂ）Ｘ１００
Ａ：チューブ浸漬後のＴＮＧの濃度
Ｂ：チューブ浸債前のＴＮＧの濃度
本実施例の方法により算出したＴＮＧの残存率を本発明
の超低密度ポリエチレンチューブとポリ塩化ビニル製の
材料からなるチューブと比較した結果を表１に示す（表
１中、ＬＬＤＰＥは超低密度ポリエチレン、ＰＶＣはポ
リ塩化ビニルを示す、）
表１の結果より、本発明のチューブは、ポリ塩化ビニル
製のチューブと比較して、ＴＮＧの吸着量が、非常に少
ないことがわかる。Residual rate = (A/B)X100 A: Concentration of TNG after tube immersion B: Concentration of TNG before tube immersion The residual rate of TNG calculated by the method of this example is compared with the ultra-low density polyethylene tube of the present invention The results of comparison with tubes made of polyvinyl chloride materials are shown in Table 1. It can be seen that the amount of TNG adsorbed is very small compared to the tube made of polyvinyl chloride.
また本発明のチューブは、柔軟性も充分に有しており、
輸液セット、カテーテル等の医療用具に使用するのに充
分であった。Furthermore, the tube of the present invention has sufficient flexibility,
It was sufficient for use in medical devices such as infusion sets and catheters.
（発明の効果）
以上説明したように、本発明のチューブにおいては、Ｔ
ＮＧの吸着がほとんどなく、かつ充分な柔軟性を有する
ので、ＴＮＧを静脈注入するための医療用具に使用する
チューブとして最適なものであり、正確なＴＮＧの投与
が実施できる。(Effects of the Invention) As explained above, in the tube of the present invention, T
Since it has almost no adsorption of NG and has sufficient flexibility, it is ideal as a tube for use in medical equipment for intravenously injecting TNG, allowing accurate administration of TNG.
表１
特許出願人 川澄化学工業株式会社
手続補正書（自発）
１、事件の表示 ７１．・１１７゜
−’ −−’ ７’ ｊり一り′
昭和６１年７月４日付提出の特許願
２、発明の名称
ニトログリセリン静注用チューブ
３、補正をする者
事件との関係 特許出願人
住所（居所）
〒１４０
東京部品用区南大井３丁目２８番１５号氏名（名称）
４、補正の対象
本願明細書中１３、発明の詳細な説明Ｊの欄
補 正 内 容
１０本願明細書第３頁第１Ｏ行目から第１１行目にｒＴ
ＮＧ・・・ｙＪ整した。ｊとあるのをｒＴＮＧ（日本化
薬製）０．５ｍｇ／ｍｌを莫留水で１０倍に希釈し、Ｔ
ＮＧ水溶液を調整した。」と訂正する。Table 1 Patent applicant Kawasumi Chemical Industry Co., Ltd. Procedural amendment (voluntary) 1. Indication of the case 71.・117゜−'−−'7'jriichiri' Patent application 2 filed on July 4, 1986, name of invention nitroglycerin intravenous injection tube 3, relationship with the amended person case Patent applicant Address (residence) 3-28-15, Minami-Oi, Parts Yo-ku, Tokyo 140 Name 4. Subject of amendment 13. Amendment to column Detailed Description of the Invention J Contents 10 Specification No. rT on page 3, line 10 to line 11
NG...yJ was adjusted. 0.5 mg/ml of rTNG (manufactured by Nippon Kayaku) was diluted 10 times with distilled water, and T
An NG aqueous solution was prepared. ” he corrected.
２、本願明細書第３頁第１４行目に［・・・ＴＮＧ水溶
液中・・・」とあるのを
ｆ・・・ＴＮＧ水溶液２．０ｍｌ中・・・Ｊと訂正する
。2. In the 14th line of page 3 of the present specification, the phrase [...in TNG aqueous solution...] is corrected to f...in 2.0 ml of TNG aqueous solution...J.
３、本願明細書第４頁第６行目にｒＬＬＤＰＥ」とある
のをｒＶＬＤＰＥＪと訂正する。3. In the 6th line of page 4 of the present specification, "rLLDPE" is corrected to rVLDPEJ.
４、本願明細書第５頁表１中にｒ Ｌ Ｌ Ｄ Ｐ Ｅ
ＪとあるのをｒＶＬＤＰＥＪと訂正する。4. r L L D P E in Table 1 on page 5 of the specification of the present application
Correct "J" to "rVLDPEJ".
Claims (1)
されるチューブにおいて、比重０．８９以下の超低密度
ポリエチレンから形成されたことを特徴とするニトログ
リセリン静注用チューブ。A nitroglycerin intravenous injection tube used as a medical device for intravenous injection of nitroglycerin, characterized in that it is made of ultra-low density polyethylene with a specific gravity of 0.89 or less.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61156219A JPS6315957A (en) | 1986-07-04 | 1986-07-04 | Tube for intravenous injection of nitroglycerine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61156219A JPS6315957A (en) | 1986-07-04 | 1986-07-04 | Tube for intravenous injection of nitroglycerine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6315957A true JPS6315957A (en) | 1988-01-23 |
| JPH0148775B2 JPH0148775B2 (en) | 1989-10-20 |
Family
ID=15622959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61156219A Granted JPS6315957A (en) | 1986-07-04 | 1986-07-04 | Tube for intravenous injection of nitroglycerine |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6315957A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020059474A1 (en) * | 2018-09-21 | 2020-03-26 | 小林製薬株式会社 | Pharmaceutical composition |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS576661A (en) * | 1980-05-09 | 1982-01-13 | Warner Lambert Co | Set for injecting nitroglycerin |
| JPS59114146U (en) * | 1983-01-25 | 1984-08-01 | 日本化薬株式会社 | IV drip set |
-
1986
- 1986-07-04 JP JP61156219A patent/JPS6315957A/en active Granted
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS576661A (en) * | 1980-05-09 | 1982-01-13 | Warner Lambert Co | Set for injecting nitroglycerin |
| JPS59114146U (en) * | 1983-01-25 | 1984-08-01 | 日本化薬株式会社 | IV drip set |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020059474A1 (en) * | 2018-09-21 | 2020-03-26 | 小林製薬株式会社 | Pharmaceutical composition |
| US11833123B2 (en) | 2018-09-21 | 2023-12-05 | Kobayashi Pharmaceutical Co., Ltd. | Pharmaceutical composition |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0148775B2 (en) | 1989-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW403664B (en) | Oriented medical tubing | |
| Zimmermann | Intravenous tubing for parenteral therapy | |
| George et al. | Metabolism of isoprenaline in the intestine | |
| GB951989A (en) | A new imidazoline derivative and its acid addition salts and processes for their manufacture | |
| US4266542A (en) | EVA Formulation having improved properties | |
| US2671748A (en) | Composition of matter | |
| Tsao et al. | Central venous catheter-induced endocarditis: human correlate of the animal experimental model of endocarditis | |
| JPS6315957A (en) | Tube for intravenous injection of nitroglycerine | |
| Koch et al. | Bile-blood fistula: a complication of percutaneous transhepatic cholangiography | |
| EP0801571A1 (en) | Soluble 2-chloro-2'-deoxyadenosine formulations | |
| Lipman | Effect of buffering on the incidence and severity of cephalothin-induced phlebitis | |
| JPS6058927A (en) | Blood platelet preparation labeled with radioactive isotope | |
| Rhode et al. | Method for continuous intravenous administration of nutritive solutions suitable for prolonged metabolic studies in dogs | |
| Hall et al. | Hypothermia produced by nicotine perfused through the cerebral ventricles of the unanaesthetized monkey | |
| Lemmel et al. | Continuous long-term intravenous infusion in unrestrained mice—Method | |
| HAYES et al. | Experimental evaluation of concentrated solutions of iothalamic acid derivatives as angiographic contrast media | |
| US2766174A (en) | Self-sterilizing antihistaminic solution of 3-(p-chlorophenyl)-3-(2-pyridyl)-n, n-dimethyl propylamine | |
| Rapaport et al. | Fibrinogen response to turpentine and endotoxin in busulfan-treated rabbits | |
| JPH03505600A (en) | plasticized polymer composition | |
| McElnay et al. | Binding of human insulin to burette administration sets | |
| Khalouf et al. | Stretching with obstruction of an epidural catheter | |
| Yalkowsky et al. | Stability of E-type prostaglandins in triacetin | |
| Curry et al. | Destruction of chlorpromazine during absorption by rat intestine in vitro. | |
| JP2005253721A (en) | Medical tube | |
| Splinter et al. | Recovery of phenytoin suspension after in vitro administration through percutaneous endoscopic gastrostomy Pezzer catheters |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |